London, UK – 23rd March 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announced the opening of a new office in Taiwan. This expansion strengthens Ergomed's clinical research and consultancy presence in Asia, and is a key element of the company's strategic growth plan set out at the IPO.
This is Ergomed's first office in Asia. The Company has decided to invest in organic growth as a first step. The new subsidiary company in Taipei will act as a hub for business activity across the country and the wider Asian market, ensuring Ergomed is best placed to support existing and new clients working in the region.
Miroslav Reljanovic, Chief Executive Officer of Ergomed plc commented: "We are very pleased to open an office in Taiwan where there is an expanding life science market. The Taiwan operations are in line with our strategy to expand in Asia through organic growth and acquisitions as stated at our IPO. We are currently working with some exciting Taiwanese companies and the new office gives us the platform to offer our services to pharma and biotech companies in the entire region.It is important for our clients in Taiwan to have local on-the-ground support integrated with an international drug development capability, and we can now provide that very effectively through our Taipei office."
The Taiwan operations will be led by the new Executive Director Global Clinical Operations, Dr Sy-Shi Wang who joined Ergomed in 2014. Dr Wang brings extensive international experience including Asia. She has worked previously at global US biotechnology companies with responsibility for all global strategic and executional aspects of clinical development.
Ergomed has particular expertise in the clinical development of oncology, immunology and orphan drugs. This along with its Co-Development Business – where Ergomed leverages its expertise and services in return for carried interest in the drugs under development – are areas of focus for the Asian operations. The new team will be backed by the full resources of Ergomed's extensive worldwide operations currently in over 40 countries.
Dr Sy-Shi Wang,Executive Director Global Clinical Operations of Ergomed, said: "Taiwan is a market with tremendous potential and home to some of the world's most progressive, forward-thinking organisations in biopharma development. I am very excited by the opportunity this presents and the foothold it provides Ergomed to expand further our Asian presence."